nejm semaglutide ckd The FLOW trial: #semaglutide significantly reduces the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and chronic kidney disease. #CKD @NEJM https://t.co/raVb2h96Pp FLOW Study Highlights: How Semaglutide

HDL cholesterol may increase slightly, though this effect is less consistent

You should skip that days dose and resume your strict routine the following morning

The authors of the new study said they saw similar changes in markers of growth such as height, bone age, and puberty status between the treatment and placebo groups

Dual Incretin Research Peptide Mechanism of Action Preclinical studies have examined this dual incretin research peptide across two primary receptor pathways: GLP-1 Receptor (GLP-1R) Activation Glucose-dependent insulinotropic signaling and beta-cell functional studies Gastric emptying rate modulation in metabolic models Hypothalamic appetite-regulatory pathway research Incretin hormone signaling cascade studies GIP Receptor (GIPR) Activation Nutrient-responsive insulin secretion pathway research Adipocyte signaling and lipid metabolism studies Post-prandial glucose handling models Synergistic incretin co-activation research The combined GLP-1R/GIPR agonism profile referred to in research literature as twincretin activity enables investigation of bimodal incretin signaling

JAMA 330 , 14481458 (2023)